Invitrogen Bets Deal to Donate Cell-Based Assay Tools to NCGC Will Train Emerging Client Base | GenomeWeb

This article has been updated from a previous version to include a comment from an Odyssey Thera official regarding the company's technology.

The National Institutes of Health's Chemical Genomics Center will use cell lines and reporter gene technology from Invitrogen to identify activators or inhibitors of disease pathways such as the MAP kinase pathway, Jak-STAT pathway, and hypoxia response, Invitrogen said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.